Patrick Goodman, MD
Pain Medicine · Tifton, GANPI 1639392558
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 340 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by Boston Scientific at 25.3% of the total.
Across 340 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- AbbVie$800
- Collegium Pharmaceutical, Inc.$741
- Pfizer$396
- Scilex Pharmaceuticals Inc.$372
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$330
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,614100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 44 | $1,676 |
| AbbVie(2 entities) | 53 | $800 |
| Collegium Pharmaceutical, Inc. | 46 | $741 |
| Pfizer | 22 | $396 |
| Scilex Pharmaceuticals Inc. | 19 | $372 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $330 |
| Teva Pharmaceuticals USA, Inc. | 20 | $326 |
| Amgen(2 entities) | 17 | $295 |
| Lilly USA, LLC | 15 | $254 |
| Almatica Pharma LLC | 11 | $193 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $128 |
| Eisai Inc. | 7 | $121 |
| Biohaven Pharmaceuticals, Inc. | 6 | $93 |
| Pacira Therapeutics, Inc. | 6 | $85 |
| Novartis | 5 | $85 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $78 |
| Forte Bio-pharma LLC | 1 | $75 |
| Averitas Pharma Inc. | 2 | $66 |
| Vertex | 3 | $63 |
| Redhill Biopharma Inc. | 4 | $61 |
| Idorsia Pharmaceuticals US Inc | 4 | $59 |
| Sentynl Therapeutics, Inc. | 4 | $54 |
| Johnson & Johnson | 2 | $44 |
| Supernus Pharmaceuticals, Inc. | 3 | $37 |
| Shionogi Inc | 2 | $30 |
| Nalu Medical, Inc. | 2 | $28 |
| IBSA Pharma Inc. | 2 | $28 |
| Biodelivery Sciences International, Inc. | 2 | $28 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Pacira Pharmaceuticals Incorporated | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $13 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,614 in reported general payments places this provider in the 75th percentile of 203 pain medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 5,522 | $152,460 |
| Xtampza ErOxycodone Myristate | 170 | $107,248 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 2,767 | $77,276 |
| UbrelvyUbrogepant | 50 | $63,274 |
| Nurtec OdtRimegepant Sulfate | 32 | $51,775 |
| Fentanyl | 465 | $45,682 |
| RelistorMethylnaltrexone Bromide | 21 | $43,194 |
| Aimovig AutoinjectorErenumab-Aooe | 56 | $40,828 |
| MovantikNaloxegol Oxalate | 94 | $37,852 |
| ZtlidoLidocaine | 60 | $35,688 |
| LinzessLinaclotide | 55 | $29,986 |
| Buprenorphine | 75 | $28,002 |
| Diclofenac Sodium | 439 | $24,083 |
| Emgality PenGalcanezumab-Gnlm | 31 | $22,103 |
| Tramadol Hcl | 2,287 | $20,337 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er | $741 | $125,771200 claims |
| AbbVieUbrelvy, Linzess | $800 | $93,260105 claims |
| PfizerNurtec Odt | $396 | $51,77532 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $330 | $43,19421 claims |
| Redhill Biopharma Inc.Movantik | $61 | $37,85294 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $372 | $35,68860 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 203 pain medicine providers in Georgia.
Other pain medicine in Tifton
- Rutvij ShahColumbus$86K
- Siddardth UmapathyFort Eisenhower$41K
- Susheel DuaAtlanta$36K
- Subodh AgrawalAthens$34K
- Jose MathewLawrenceville$27K
- Zhuo SunAugusta$26K
- Maged HamzaGainesville$24K
- Ankur PatelGainesville$21K
- Margaret RisoGainesville$19K
- Steven HanlingAugusta$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.